Strong sales growth in terms of price challenges

• Revenue: 8.1 billion US dollars, an increase of 9% compared to the previous year.

• Volume growth: 14% increase from key brands.

• Product sales growth: 11% compared to the previous year.

• Net sales price: Reduced by 6%.

• Non-GAAP operating range: 45.7%.

• Non-GAAP-F & E-growth: 12% compared to the previous year.

• Free Cashflow: 1.0 billion US dollars in the first quarter.

• Investment expenses: 400 million US dollars in the first quarter.

• Non-GAAP tax rate: 14.6%.

• Intactment pension: 2.9 billion US dollars in the first quarter of 2025.

• Dividend: 2.38 USD per share, an increase of 6% compared to the first quarter of 2024.

• Repatha sale: 656 million US dollars, an increase of 27% compared to the previous year.

• Detailing sales: 442 million US dollars, an increase of 29% compared to the previous year.

• Prolia sales: Almost 1.1 billion US dollars, an increase of 10% compared to the previous year.

• Value of rare diseases portfolio: 1 billion US dollars, an increase of 3% compared to the previous year.

• Biosimilar portfolio sale: 735 million US dollars, an increase of 35% compared to the previous year.

• Global product sales growth: 14% in the USA.

Appearance date: May 1, 2025

You can find the complete copy of the earnings call in the complete earnings call.

• Amgen Inc (Nasdaq: AMGN) recorded sales growth of 9% compared to the previous year with a volume rise of 14%, which is due to a strong demand for its innovative medication.

• The company's biosimilars portfolio provided sales of over 700 million US dollars and was an increase of 35% compared to the previous year.

• Amgen Inc (Nasdaq: Amgn) has launched three new products or indications and initiated four new phase -3 studies, which showed robust pipeline progress.

• Repatha's sales rose by 27%compared to the previous year, with the patient's access and a strong growth curia significantly improved.

• The company received the FDA approval for uplizna from IGG4-related diseases, expanded its portfolio for rare diseases and demonstrated its leadership in innovative treatments.

• Amgen Inc (Nasdaq: AMGN) was compared to a decline in net sales price by 6%, which partially extensively the two -digit sales growth.

• The sale of Tepezza and Krystexxa was disadvantageously influenced by changes in the US wholesaler inventory level, which influenced the performance of the rare disease portfolio.

• The company expects the quarterly sales fluctuations for Wezlana in the United States, without sales in the second quarter to be expected in the second quarter.

• Amgen Inc (Nasdaq: Amgn) navigates uncertainties related to tariffs and taxes that could affect the long -term business strategy.

• The company assumes that non-GAAP expenditure will grow by about 20% in 2025, which is due to increased systems in pipeline assets in the late stage, which puts the margins under pressure.

Q: What should we expect from the ADA presentation regarding Maritide and can you comment on the potential study on cardiovascular results? A: James Bradner, Executive Vice President and Development, and Chief Scientific Officer, explained that the ADA presentation will concentrate on the strong effectiveness and tolerance of Maritides in the phase -2 study without plateau in weight loss after 52 weeks. The presentation will also contain new mechanistic data. With regard to the study on cardiovascular results, the details are not passed on at this time, but a wide phase -3 program is underway.